• Alias: CB7630
    • Selectively and irreversibly inhibits 17-α-hydroxylase/C17,20-lyase (CYP17), an enzyme required for androgen biosynthesis. The inhibition of CYP17 results in increased mineralocorticoid production by the adrenals.
    • FDA approved for castrate-resistant prostate cancer
    • Dose: 1,000 mg PO daily with prednisone. Give on a fasting stomach 1 hour before and 2 hours after meal
    • Half-life: 14.4 to 16.5 hours
    • Metabolism: Potent CYP3A4 substrate
    • Side effects: Peripheral edema, fatigue, hypertension, hyperglycemia/hypertriglyceridemia, lymphopenia
    Other topics in Targeted and Immunotherapy Agents